<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81802">
  <stage>Registered</stage>
  <submitdate>11/01/2007</submitdate>
  <approvaldate>17/01/2007</approvaldate>
  <actrnumber>ACTRN12607000055404</actrnumber>
  <trial_identification>
    <studytitle>Effects of calcium and vitamin D supplementation on bone mineral density and bone related chemistry in elderly women</studytitle>
    <scientifictitle>A 5-year randomised controlled trial of the effects of calcium and vitamin D supplementation on bone mineral density and bone related chemistry in elderly ambulant Australian women</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Elderly healthy women</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This was a 5-year randomised, controlled, double-blind study.                                                                                                                                                                                         Participants were randomised to orally receive either 1000 IU ergocalciferol and 1200 mg calcium (Ca) in the form of carbonate (CalD group), 1200 mg Ca and placebo vitamin D (Ca group) per day over the 5 years.</interventions>
    <comparator>Participants were randomised to orally receive placebo Ca and placebo vitamin D (placebo group) per day over the 5 years.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1) Bone structure of hip as measured by Dual Energy X-ray Absorptiometry </outcome>
      <timepoint>Measurements were made at baseline, 1, 3 and 5 years.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2) Plasma 25-hydroxy vitamin D</outcome>
      <timepoint>Measurements were made at baseline, 1, 3 and 5 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1) Plasma parathyroid hormone</outcome>
      <timepoint>Measurements were made at baseline, 1, 3 and 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2) Plasma and urinary calcium</outcome>
      <timepoint>Measurements were made at baseline, 1, 3 and 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3) Biochemical markers of bone turnover</outcome>
      <timepoint>Measurements were made at baseline, 1, 3 and 5 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Likely to survive a five-year study.</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Receiving bone active agent. There were no other specific exclusions so that the results could be generalised to the whole ambulant population.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subject numbers was allocated by personnel having no contact with study participants.</concealment>
    <sequence>Computer-generated randomisation sequence.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The study subjects, therapists, assessors and data analysts remained blinded to the treatment code until all the data had been entered, evaluated for accuracy and the a-priori hypotheses reviewed.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>21/07/1998</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A Professor RL Prince</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Healthway Health Promotion Foundation of Western Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australasian Menopause Society</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian National Health and Medical Research Council</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>The University of Western Australia and</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname> the Sir Charles Gairdner Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a 5-year randomised, double blind, placebo controlled study to evaluate the relative benefits of vitamin D and calcium supplementation and calcium alone compared to placebo on hip bone mineral density and bone related biochemistry in ambulant elderly Western Australian women aged 70-80 years at baseline.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Western Australia</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/07/1998</ethicapprovaldate>
      <hrec>RA/4/1/1553</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A Professor Richard Prince</name>
      <address>Bone and Calcium Research Group
School of Medicine and Pharmacology
University of Western Australia
Department of Endocrinology and Diabetes
1st Floor C Block
Sir Charles Gairdner Hospital
Hospital Ave, Nedlands WA 6009</address>
      <phone>+61 8 93464111</phone>
      <fax>+61 8 93462733</fax>
      <email>rlprince@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A Professor Richard Prince</name>
      <address>Bone and Calcium Research Group
School of Medicine and Pharmacology
University of Western Australia
Department of Endocrinology and Diabetes
1st Floor C Block
Sir Charles Gairdner Hospital
Hospital Ave, Nedlands WA 6009</address>
      <phone>+61 8 93464111</phone>
      <fax>+61 8 93462733</fax>
      <email>rlprince@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>